Skip to content
Home
Close Home
Open Home
Journal information
Editorial board
Operations manual
Editorial policies
Code of conduct for authors
Code of conduct for reviewers
Ahead of print
Read
Close Read
Open Read
Archive
TOC Alert
Current issue
Information
Close Information
Open Information
Editorial & Peer Review
Ethical policies
Funding
Complaints and appeals
Open access and licensing
Authors
Sponsorship
Contact
Publish
Close Publish
Open Publish
Instructions to authors
Online submission
Home
Journal Information
Editorial Board
Operations Manual
Editorial Polices
Code of conduct for authors
Code of conduct for reviewers
Ahead of print
Read
Archive
Toc Alert
Current issue
Information
Editorial & Peer review
Ethical policies
Funding
Procedure for complaints and/or appeals
Open access & Licensing
Authors
Sponsors
Contact
Publish
Authors Instructions
Online submission
Home
Journal Information
Editorial Board
Operations Manual
Editorial Polices
Code of conduct for authors
Code of conduct for reviewers
Ahead of print
Read
Archive
Toc Alert
Current issue
Information
Editorial & Peer review
Ethical policies
Funding
Procedure for complaints and/or appeals
Open access & Licensing
Authors
Sponsors
Contact
Publish
Authors Instructions
Online submission
ES
EN
0,00
€
0
Cart
TOC Alert
2007
Three-year Extended Follow-up of the 2NN Study: Nevirapine versus Efavirenz
New Trials Comparing Protease Inhibitors and Nonnucleoside Analogs will Assess Reductions in Cardiovascular Risk Besides Antiviral Efficacy in First-line Therapies
HIV Guidelines
HIV Guidelines
Nevirapine or Efavirenz for Replacing. Protease Inhibitors?
Hopes for New Cyclophilin Inhibitors of Hepatitis C Virus in HIV Coinfected Patients
HIV Guidelines
HIV Conferences
HIV Conferences
Nevirapine Once Daily is Moving Further Steps